Rigel Pharma (RIGL): Restructuring A Positive - Jefferies

September 16, 2016 7:55 AM EDT
Get Alerts RIGL Hot Sheet
Price: $2.23 -0.89%

Rating Summary:
    6 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 30 | New: 23
Trade RIGL Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies analyst, Eun Yang, reiterated her Buy rating on shares of Rigel Pharmaceuticals (NASDAQ: RIGL) and raised the price target to $9 from $8.50 after the company announced a cost restructuring to prioritize fostamatinib commercialization. There are no changes planned for the development plans of IRAK inhibitor R191 however.

Yesterday, RIGL announced a ~38% workforce reduction (46 positions), largely in research, which is expected to complete by 12/15/16. RIGL expects the reduction to yield ~$17M-$20M in cost savings annually following a one-time $5.7M severance charge in 3Q16. The company will retain a smaller research organization to continue active programs (e.g., fosta in IgAN & AIHA, R191). RIGL also announced retirement of co-founder/EVP & president of discovery and research Donald Payan, and appointment of Eldon Mayer as EVP & CCO. Mr. Mayer previously held commercial roles at Questcor Pharmaceuticals, Connetics Corporation, Chiron Corpoartion, Alza Corporation & Schering-Plough.

For an analyst ratings summary and ratings history on Rigel Pharmaceuticals click here. For more ratings news on Rigel Pharmaceuticals click here.

Shares of Rigel Pharmaceuticals closed at $3.45 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Changes, Management Comments

Related Entities

Jefferies & Co, Layoffs

Add Your Comment